Table 1.
Patient identification and previous cancer therapies
| Patient | Age -yr | Primary Tumor site | Treatment date (months after first diagnosis) | Liver Volume -ccm | CTV -ccm | With ≥10 Gy irradiated Liver Volume -ccm | Chemotherapy prior to brachytherapy | Chemotherapy during follow-up | Liver resection or local treatment prior to brachytherapy |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 84 | Colon | 79 | 1063 | 66.7 | 249.5 | n/a | none | Right hemihepatectomy, RFA |
| 2 | 69 | Gastric | 16 | 1720 | 340.4 | 689 | CAP+DOC, CAP | none | none |
| 3 | 66 | Lung | 10 | 2135 | 30.6 | 205 | none | GEM | RFA |
| 4 | 66 | Colon | 13 | 1296 | 3.64 | 19 | FOLFOX | none | none |
| 5 | 66 | Breast | 83 | 1206 | 2.7 | 79.5 | TAM, END+EPI+5FU/FA, EXE | EXE | none |
| 6 | 63 | Breast | 18 | 1301 | 41.5 | 277.7 | VP 16+JM8, DOC | GEM, DOC+CAP | none |
| 7 | 72 | Colon | 30 | 1499 | 23.1 | 141 | 5FU/FA, FOLFOX | none | Wedge resection S4 |
| 8 | 30 | Breast | 12 | 1334 | 9.2 | 90.6 | DOC+EPI, TAM+LEU, VIN+ Anti-Her-2/neu, 5FU/FA | CAP | none |
| 9 | 61 | Breast | n/a | 1406 | 15.1 | 91.3 | none | none | Wedge resection S4 |
| 10 | 70 | Colon | 14 | 2672 | 20.5 | 181 | 5FU/FA | none | none |
| 11 | 58 | Colon | 49 | 1531 | 36.4 | 236 | 5FU/FA, FOLFIRI, FOLFOX | none | none |
| 12 | 69 | Colon | 43 | 1610 | 100.7 | 381.6 | FOLFIRI, FOLFOX, 5FU/FA, Anti-EGFR +CPT11 | Anti-EGFR+CPT11 | none |
| 13 | 61 | Colon | n/a | 1350 | 123.6 | 327.6 | FOLFOX+Anti-VEGF, 5FU/FA, | FOLFOX | Right hemihepatectomy, RFA |
| 14 | 72 | Renal | n/a | 1170 | 1.7 | 49.4 | none | none | Wedge resection, RFA |
| 15 | 55 | Colon | 56 | 1484 | 58.5 | 370 | FOLFIRI, FOLFOX | none | Right hemihepatectomy |
| 16 | 62 | Colon | 20 | 1247 | 4.9 | 104.5 | FOLFOX | none | none |
| 17 | 56 | Renal | 6 | 822 | 30.5 | 137.7 | none | SOR | none |
| 18 | 55 | Colon | 22 | 1170 | 7.3 | 145 | CAP+L-OHP, CAP+L-OHP+ Anti-VEGF | none | Right hemihepatectomy |
| 19 | 69 | Breast | 34 | 1073 | 10.1 | 60.1 | EPI+DOC, Anti-Her-2/neu +CAP+VIN, SDX 105, DOC | none | none |
| 20 | 53 | Breast | 125 | 1054 | 0.8 | 22.2 | VP 16+CAR, DOC+ADR, TAM, EXE, LET, 5FU/FA+CTX+EPI, FUL, GEM | none | none |
| 21 | 52 | Breast | 16 | 1650 | 7.1 | 102 | VP 16+JM8, LET | CAP | none |
| 22 | 76 | Renal | 156 | 930 | 2.9 | 14.7 | none | none | Wedge resection, RFA |
| 23 | 77 | Breast | 80 | 1503 | 28.9 | 100.7 | CAP | none | none |
Abbreviations: Bendamustine (SDX 105), Bevacizumab (Anti-VEGF), Capecitabine (CAP), Carboplatin (JM8), Cetuximab (Anti-EGFR), Cyclophosphamide (CTX), Docetaxel (DOC), Doxorubicin (ADR), Endoxane (END), Epirubicin (EPI), Etoposide (VP 16), Exemestan (EXE), 5-Fluorouracil (5FU), Folic acid (FA), 5-Fluorouracil/Folic acid +Irinotecan (FOLFIRI), 5-Fluorouracil/Folic acid +Oxaliplatin (FOLFOX), Fulvestrant (FUL), Gemcitabine (GEM), Irinotecan (CPT 11), Letrozole (LET), Leuprorelin (LEU), Oxaliplatin (L-OHP), Sorafenib (SOR), Tamoxifen (TAM), Trastuzumab (Anti-Her-2/neu), Vinorelbine (VIN).
Combined applications are marked by +. Comma marks indicate sequential chemotherapeutic regimens.
Clinical Target Volume (CTV), Radiofrequency Ablation (RFA)